You are here: Industry Insights > Cancer

News List

MorphoSys, I-Mab Announce IND Application Clearance for Advanced Cancer Treatment americanpharmaceuticalreview
September 27, 2020
MorphoSys and I-Mab jointly announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
Gilead may soon buy Immunomedics in deal over $20 billion expresspharma
September 24, 2020
The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports.
Exelixis, NBE join forces for discovery and development of ADCs for cancer pharmaceutical-business-review
September 24, 2020
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific ...
$65 million expansion to HPAPI manufacturing facility europeanpharmaceuticalreview
September 24, 2020
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
Bristol Myers Squibb’s Opdivo shows benefit in oesophageal cancers pharmatimes
September 23, 2020
Bristol Myers Squibb’s Opdivo (nivolumab) demonstrated promise in a phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction (GEJ) cancers who had previously receiving neoadjuvant chemoradiation therapy (CRT) and ...
University of Edinburgh spinout Cellinta will develop gene therapies for cancer pharmatimes
September 22, 2020
A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer.
Keytruda/Lenvima combo shows promise in hard-to-treat cancers pharmatimes
September 22, 2020
MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers pharmatimes
September 21, 2020
Bayer’s tumour agnostic therapy Vitrakvi has demonstrated sustained, long-term efficacy and safety in a number of tropomyosin receptor kinase (TRK) fusion-positive cancers, including lung and thyroid tumours.
Palleon Pharmaceuticals secures $100m in Series B funding pharmaceutical-technology
September 18, 2020
Palleon Pharmaceuticals has raised $100m in a Series B financing round to develop drugs targeting glycan-mediated immune regulation to treat cancer and inflammatory diseases.
Scientists at University of Sheffield discover new drug to treat pancreatic cancer expresspharma
September 18, 2020
Scientists at the University of Sheffield inform that they have invented a new drug which could improve life expectancy and quality for patients with hard-to-treat cancers, such as pancreatic cancer and relapsed breast cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page